Freire de Carvalho Jozélio, Sherer Yaniv, Shoenfeld Yehuda
Rheumatology Division, São Paulo University School of Medicine, São Paulo, Brazil.
Thromb Haemost. 2007 Dec;98(6):1157-9.
Anti-oxidised low-density lipoprotein (anti-oxLDL) antibodies are a heterogeneous group of autoantibodies including both pathogenic and protective subsets. Whereas in most studies the levels of anti-oxLDL antibodies were associated with enhanced atherosclerosis as evaluated by different methods, immunization with oxLDL leads to elevated levels of anti-oxLDL and protection against atherosclerosis. Anti-oxLDL can also be used for immunomodulation of atherosclerosis (i.e. possible therapeutic use of intravenous immunoglobulin, oral tolerance). More specific autoantibodies out of total anti-oxLDL should be selected, for instance, anti-oxLDL/beta-2-glycoprotein I complex, hence defining the fine-tuning of anti-oxLDL antibodies might detect which autoantibodies are pathogenic and which can be used therapeutically.
抗氧化低密度脂蛋白（anti-oxLDL）抗体是一类异质性自身抗体，包括致病性和保护性亚群。尽管在大多数研究中，通过不同方法评估发现anti-oxLDL抗体水平与动脉粥样硬化的加重有关，但用氧化型低密度脂蛋白（oxLDL）免疫会导致anti-oxLDL水平升高并对动脉粥样硬化起到保护作用。Anti-oxLDL还可用于动脉粥样硬化的免疫调节（即静脉注射免疫球蛋白、口服耐受的可能治疗用途）。应从总的anti-oxLDL中选择更具特异性的自身抗体，例如抗oxLDL/β2-糖蛋白I复合物，因此明确anti-oxLDL抗体的精细调节可能会检测出哪些自身抗体具有致病性，哪些可用于治疗。
